Glucotrack Repurchases Over 90% Of Series A Warrants From $10M Public Offering, Advancing Capital Strategy And Diabetes Device Development

Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully repurchased over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025.

The repurchase was completed as part of the Company's capital formation strategy and reflects its continued confidence in its product development of a long-term implantable continuous blood glucose monitoring system for people living with diabetes. The Series A Warrants and Series B Warrants were originally issued in connection with the $10M Public Offering completed in November 2024.

Under the terms of the transaction, the Company repurchased approximately 49,700 Series A Warrants, funded with existing cash on hand. Following the repurchase, approximately 4,300 Series A Warrants remain outstanding of which majority of these are also expected to be repurchased. The Series B Warrants were previously extinguished in exchange for common stock as reported in the Form 10Q for the period ending March 31, 2025.